Publication | Closed Access

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Surgical OncologyGastrointestinal OncologyMedicineHepatobiliary TumorBiliary CancerPathologyCancer TreatmentFgfr2 FusionsMature ResultsOncologyRadiation OncologyCancer ResearchMolecular OncologyMetastatic Cholangiocarcinoma